Latest Strategic Initiatives News

Resolute Mining has outlined its 2026 production guidance targeting up to 275,000 ounces of gold and revealed ambitious plans to more than double output by 2028 through key African project expansions.

Nuix Limited has reported robust half-year results for 1H26, highlighted by a 148% increase in Nuix Neo Annualised Contract Value and a significant boost in profitability and cash flow.

thl reports an 11% rise in underlying NPAT for H1 FY26 and sets a bullish FY26 guidance, underpinned by strategic divestments and cost efficiencies.

Chorus Limited has reported a strong half-year performance driven by fibre broadband growth, operational efficiencies, and a return to profitability, while launching initiatives to boost digital inclusion.

Mesoblast Limited is set to release its half-year financial results and operational update, spotlighting its FDA-approved cell therapy and expanding international partnerships.

Contact Energy has issued over 51 million new shares at NZD 8.75 each, representing a 5.17% increase in its ordinary shares, aiming to strengthen its shareholder base through a carefully structured placement.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing for its lead ophthalmology product, Elate Ocular®, alongside key global partnerships and a $2.4 million capital injection from a major shareholder.

Boom Logistics has reported a record half-year revenue of $142.2 million for 1H FY26, alongside upgraded earnings guidance and an expanded share buy-back program, signalling strong operational momentum despite sector challenges.

Zip Co Limited has announced a $50 million on-market share buy-back program starting in March 2026, signalling confidence in its financial position and commitment to capital management.

Guzman y Gomez has reported a robust first half of FY26, delivering strong revenue and profit growth alongside significant restaurant network expansion in Australia and the US.

EQT Holdings Limited has reported a strong half-year performance with an 11.8% revenue increase and a 67% surge in profit after tax, while announcing a fully franked interim dividend of 56 cents per share despite suspending its dividend reinvestment plan.

Medical Developments International (MVP) reported an 8% revenue increase driven by strong Penthrox growth, despite a slight EBIT loss impacted by foreign exchange. The company advances pediatric approvals and targets further volume gains.